居住在美国是阿尔茨海默病的危险因素吗？

IF 3.4 3区医学 Q2 NEUROSCIENCES

Journal of Alzheimer's Disease Pub Date : 2025-07-03 DOI:10.1177/13872877251356682

Poul F Høilund-Carlsen, Abass Alavi, Tommaso Costa, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio

{"title":"居住在美国是阿尔茨海默病的危险因素吗？","authors":"Poul F Høilund-Carlsen, Abass Alavi, Tommaso Costa, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio","doi":"10.1177/13872877251356682","DOIUrl":null,"url":null,"abstract":"Reducing risk factors is a useful way to counteract diseases. The prevalence of Alzheimer's disease (AD) in the US is often quoted as 6.9 million out of 333 million people, or 2.1%. It is around 0.7% in the UK, 0.9% in Denmark, and worldwide the estimate is 0.5%. Alongside risk factor reduction, the Centers for Medicare and Medicaid Services could strengthen the US fight against AD by reconsidering its October 2023 decision to liberalize reimbursement of amyloid PET scans, or better yet, advise replacing these non-specific scans with FDG-PET, which shows what AD is really about: impaired regional brain function.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251356682"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is US residence a risk factor for Alzheimer's disease?\",\"authors\":\"Poul F Høilund-Carlsen, Abass Alavi, Tommaso Costa, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio\",\"doi\":\"10.1177/13872877251356682\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Reducing risk factors is a useful way to counteract diseases. The prevalence of Alzheimer's disease (AD) in the US is often quoted as 6.9 million out of 333 million people, or 2.1%. It is around 0.7% in the UK, 0.9% in Denmark, and worldwide the estimate is 0.5%. Alongside risk factor reduction, the Centers for Medicare and Medicaid Services could strengthen the US fight against AD by reconsidering its October 2023 decision to liberalize reimbursement of amyloid PET scans, or better yet, advise replacing these non-specific scans with FDG-PET, which shows what AD is really about: impaired regional brain function.\",\"PeriodicalId\":14929,\"journal\":{\"name\":\"Journal of Alzheimer's Disease\",\"volume\":\" \",\"pages\":\"13872877251356682\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13872877251356682\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877251356682","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

减少危险因素是对抗疾病的有效方法。阿尔茨海默病（AD）在美国的患病率通常被引用为3.33亿人中有690万人，占2.1%。英国约为0.7%，丹麦约为0.9%，全球估计为0.5%。除了降低风险因素，医疗保险和医疗补助服务中心可以通过重新考虑其2023年10月决定开放淀粉样蛋白PET扫描的报销，或者更好的是，建议用FDG-PET代替这些非特异性扫描，从而加强美国对AD的防治，FDG-PET显示了AD的真正意义：局部大脑功能受损。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is US residence a risk factor for Alzheimer's disease?

Reducing risk factors is a useful way to counteract diseases. The prevalence of Alzheimer's disease (AD) in the US is often quoted as 6.9 million out of 333 million people, or 2.1%. It is around 0.7% in the UK, 0.9% in Denmark, and worldwide the estimate is 0.5%. Alongside risk factor reduction, the Centers for Medicare and Medicaid Services could strengthen the US fight against AD by reconsidering its October 2023 decision to liberalize reimbursement of amyloid PET scans, or better yet, advise replacing these non-specific scans with FDG-PET, which shows what AD is really about: impaired regional brain function.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Alzheimer's Disease 医学-神经科学

CiteScore

6.40

自引率

7.50%

发文量

1327

审稿时长

2 months

期刊介绍： The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.